Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nexira has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner and a distinct art unit. Brian M Gulledge is the busiest examiner for the company, responsible for the 1 pending office action. Prosecution for Nexira is currently focused on this single examiner.
With only a single pending office action, the company's patent strategy is currently focused on a single application. The assignment to Brian M Gulledge within a distinct art unit means that the prosecution outcome is entirely dependent on this examiner's review. This concentration in the Biotechnology & Pharmaceuticals field means that the company's immediate success is tied to the standards of the art unit. Nexira must focus its efforts on meeting the specific requirements of Brian M Gulledge to resolve the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GULLEDGE, BRIAN M | 1 | 55.9% | +26.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694749 | PLANT-BASED ANTIOXIDANT ORAL COMPOSITION | GULLEDGE, BRIAN M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694749 | PLANT-BASED ANTIOXIDANT ORAL COMPOSITION | GULLEDGE, BRIAN M | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18694749 | PLANT-BASED ANTIOXIDANT ORAL COMPOSITION | GULLEDGE, BRIAN M | 1699 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNexira has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brian M Gulledge has the most, with 1 of Nexira's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
